La Chaux-de-Fonds, Switzerland, May 29, 2018 (GLOBE NEWSWIRE) —
Rhizen Pharmaceuticals S.A., a clinical-stage biotechnology company developing Tenalisib (RP6530), a highly selective and orally active dual PI3K delta/gamma inhibitor, announced today that the Phase I/II clinical development progress in Relapsed/Refractory T-cell Lymphoma (R/R TCL) and Relapsed/Refractory classical Hodgkin Lymphoma (R/R cHL) will be presented during the Poster Session at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held from June 1-5, 2018 in Chicago, Illinois, USA.
Tenalisib Phase I/II Clinical Development Progress:
- Enrollment completed in the Phase I/IB single-agent Tenalisib study in Relapsed/Refractory Peripheral T-cell Lymphoma (R/R PTCL) and Relapsed/Refractory Cutaneous T-cell Lymphoma (R/R CTCL).
- Tenalisib plus KEYTRUDA (pembrolizumab) combination clinical development program initiated in Relapsed/Refractory classical Hodgkin Lymphoma (R/R cHL) – Currently enrolling patients into a Phase I/II study (ClinicalTrials.gov Identifier: NCT03471351).
- Tenalisib single-agent Phase II study in Relapsed/Refractory indolent Non-Hodgkin Lymphoma (R/R iNHL) expected to start in 4Q 2018.
Details of the presentations are outlined below:
- Poster Title: Tenalisib, a dual PI3K delta/gamma inhibitor: Safety and efficacy results from an on-going phase I/Ib study in relapsed/refractory T-cell lymphoma
- Date and Time: Monday, June 4, 2018; 8:00 AM – 11:30 AM US CST
- Abstract Number: 7510
- Board Number: 147
- Session Title: Hematologic Malignancies – Lymphoma and Chronic Lymphocytic Leukemia
- Location: McCormick Place South, Exhibit Hall A
- Poster Title: Phase I/II study to evaluate the safety and efficacy of tenalisib, a novel PI3K delta/gamma dual inhibitor in combination with pembrolizumab in patients with relapsed/refractory classical Hodgkin lymphoma
- Date and Time: Monday, June 4, 2018; 8:00 AM – 11:30 AM US CST
- Abstract Number: TPS7584
- Board Number: 219b
- Session Title: Hematologic Malignancies – Lymphoma and Chronic Lymphocytic Leukemia
- Location: McCormick Place South, Exhibit Hall A
About Tenalisib (RP6530):
Tenalisib (RP6530) is a highly selective and orally active dual PI3K delta/gamma inhibitor with efficient translation of activity through enzyme, cell, and whole blood-based studies. Besides inhibiting growth of immortalized cancerous cell lines and primary patient leukemic/lymphoma cells, RP6530 plays a significant role in modulation of tumor microenvironment at clinically achievable concentrations. In preclinical studies, RP6530 reprograms macrophages from an immunosuppressive M2-like phenotype (pro-tumor) to an inflammatory M1-like state (anti-tumor), which can potentially enhance the activity of checkpoint inhibitors or overcome resistance to these drugs. Tenalisib obtained US FDA Fast Track Designations for treatment of relapsed/refractory peripheral T-cell lymphoma and relapsed and/or refractory cutaneous T-cell lymphoma (R/R PTCL and R/R CTCL) in addition to Orphan-Drug Designations for treatment of peripheral and cutaneous T-cell lymphoma (PTCL and CTCL).
About Rhizen Pharmaceuticals S.A.:
Rhizen Pharmaceuticals is an innovative, clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for the treatment of cancer, immune and metabolic disorders. Since its establishment in 2008, Rhizen has created a diverse pipeline of proprietary drug candidates targeting several cancers and immune associated cellular pathways. Rhizen is headquartered in La-Chaux-de-Fonds, Switzerland. For additional information, please visit Rhizen’s website, www.rhizen.com.
CONTACT: Contact: Kumar V. Penmetsa, Ph.D. Executive Vice President, Corporate Development Rhizen Pharmaceuticals S.A. Telephone: +1-267-207-5707 Email: kvp@rhizen.com
